Septo-optic dysplasia

Jump to: navigation, search
Septo-optic dysplasia
ICD-10 Q04.4
OMIM 182230
DiseasesDB 32732

WikiDoc Resources for Septo-optic dysplasia

Articles

Most recent articles on Septo-optic dysplasia

Most cited articles on Septo-optic dysplasia

Review articles on Septo-optic dysplasia

Articles on Septo-optic dysplasia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Septo-optic dysplasia

Images of Septo-optic dysplasia

Photos of Septo-optic dysplasia

Podcasts & MP3s on Septo-optic dysplasia

Videos on Septo-optic dysplasia

Evidence Based Medicine

Cochrane Collaboration on Septo-optic dysplasia

Bandolier on Septo-optic dysplasia

TRIP on Septo-optic dysplasia

Clinical Trials

Ongoing Trials on Septo-optic dysplasia at Clinical Trials.gov

Trial results on Septo-optic dysplasia

Clinical Trials on Septo-optic dysplasia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Septo-optic dysplasia

NICE Guidance on Septo-optic dysplasia

NHS PRODIGY Guidance

FDA on Septo-optic dysplasia

CDC on Septo-optic dysplasia

Books

Books on Septo-optic dysplasia

News

Septo-optic dysplasia in the news

Be alerted to news on Septo-optic dysplasia

News trends on Septo-optic dysplasia

Commentary

Blogs on Septo-optic dysplasia

Definitions

Definitions of Septo-optic dysplasia

Patient Resources / Community

Patient resources on Septo-optic dysplasia

Discussion groups on Septo-optic dysplasia

Patient Handouts on Septo-optic dysplasia

Directions to Hospitals Treating Septo-optic dysplasia

Risk calculators and risk factors for Septo-optic dysplasia

Healthcare Provider Resources

Symptoms of Septo-optic dysplasia

Causes & Risk Factors for Septo-optic dysplasia

Diagnostic studies for Septo-optic dysplasia

Treatment of Septo-optic dysplasia

Continuing Medical Education (CME)

CME Programs on Septo-optic dysplasia

International

Septo-optic dysplasia en Espanol

Septo-optic dysplasia en Francais

Business

Septo-optic dysplasia in the Marketplace

Patents on Septo-optic dysplasia

Experimental / Informatics

List of terms related to Septo-optic dysplasia


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S

Overview

Septo-optic dysplasia (SOD) (de Morsier syndrome)[1][2] is a congenital malformation syndrome manifested by hypoplasia (underdevelopment) of the optic nerve, hypopituitarism, and absence of the septum pellucidum (a midline part of the brain). In a severe case, this results in pituitary hormone deficiencies, blindness, and mental retardation. However, there are milder degrees of each of the three problems, and some children only have one or two of the three.

Neuroradiologically, intracranial malformations associated with septo-optic dysplasia include agenesis of the corpus callosum, schizencephaly, and lobar holoprosencephaly.

Causes

Septo-optic dysplasia is a developmental disorder resulting from a defect of normal embryological development. The cause of septo-optic dysplasia is not known. Rare familial recurrence has been reported, suggesting at least one genetic form (HESX1)[3], but in most cases it is a sporadic birth defect of unknown cause and does not recur again with subsequent pregnancies.

Septo-optic dysplasia is linked to young maternal age[4]. Indeed one third of Septo-optic births are the result of teenage pregnancies. These data could support an environmental origin of SOD with possible exposure to risk factors such as maternal smoking, alcohol consumption, and use of addictive drugs during early gestation. However, young maternal age in SOD was not associated with low birth weight or low gestation. This lack of association between young maternal age and an adverse developmental environment, as indicated by birth weight and gestation, suggest that maternal factors such as maternal smoking, alcohol consumption, and use of addictive drugs during early gestation are not a cause of Septo-optic dysplasia.

Diagnosis

Optic nerve

The optic nerve hypoplasia is generally manifested by nystagmus (involuntary eye movements, often side-to-side) and a smaller-than-usual optic disk. The degree of visual impairment is variable, and ranges from normal vision to complete blindness. When nystagmus develops, it typically appears by 1-4 months of age, and usually indicates that there will be a significant degree of visual impairment, but the severity is difficult to predict in infancy. Although there are many measures to compensate for visual impairment, no treatment is available to induce normal optic nerve function.

Pituitary

The degree of pituitary deficiency is also variable, and ranges from normal function, to deficiency of a single hormone, to deficiency of both anterior and posterior hormones. It is often unclear if the hypopituitarism is due to a primary pituitary dysfunction or is secondary to a hypothalmic dysfunction. Hypopituitarism in this syndrome is most often manifested by growth hormone deficiency. If severe, it can lead to diagnosis in the first days of life by causing hypoglycemia, jaundice, and micropenis (if a boy). The cause of the jaundice is unknown, and an unusual aspect of it (compared to most neonatal jaundice) is that it can be largely a conjugated (direct) hyperbilirubinemia suggestive of obstructive liver disease. It typically resolves over several weeks once hormone replacement is begun. All of the pituitary hormones can be replaced, and this is the treatment for deficiencies. Septo-optic dysplasia is one of the most common forms of congenital growth hormone deficiency.

Septum pellucidum

The brain effects are also variable and range from normal intelligence to severe mental retardation. Seizures sometimes occur. Prediction of intellectual outcome in infancy is difficult. Various types of early intervention or equivalent programs can help a child reach full developmental potential, but if brain impairment is significant, it cannot be made normal by any treatment.

Variability

Septo-optic dysplasia is a highly variable disorder. It is rare for siblings to present with identical features of the Septo-optic dysplasia spectrum. Many patients present with additional developmental defects outside the Septo-optic dysplasia triad. In particular digital defects are common.

References

  1. synd/2548 at Who Named It
  2. G. de Morsier. Études sur les dysraphies, crânioencéphaliques. III. Agénésie du septum palludicum avec malformation du tractus optique. La dysplasie septo-optique. Schweizer Archiv für Neurologie und Psychiatrie, Zurich, 1956, 77: 267-292.
  3. Dattani MT, Martinez-Barbera JP, Thomas PQ; et al. (1998). "Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse". Nat. Genet. 19 (2): 125–33. PMID 9620767. doi:10.1038/477. 
  4. McNay DE, Turton JP, Kelberman D; et al. (2006). "HESX1 mutations are an uncommon cause of septo-optic dysplasia and hypopituitarism". J Clin Endocrinol Metab. 92 (2): 691–7. 



Linked-in.jpg